Search

Displaying results 2741 - 2750 of 10000 in total
  1. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. … Through radiotracer analysis, it was determined that lacidipine displays a high membrane partition coefficient leading to accumulation of the drug in the membrane and slow rate of membrane washout [A31539

  2. Drug

    Cycloserine

    go.drugbank.com/drugs/DB00260
    ApprovedInvestigational

    Antibiotic substance produced by Streptomyces garyphalus.

  3. Drug

    Vilobelimab

    go.drugbank.com/drugs/DB16416
    ApprovedInvestigational

    [L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support … The drug is not yet fully approved for this condition.[L45849]

  4. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.

    Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidine
  5. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973]

  6. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. … [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.

  7. Drug

    Droxicam

    go.drugbank.com/drugs/DB09215
    ApprovedWithdrawn

    It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. … Droxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554].

  8. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.

  9. Drug

    AN-2718

    go.drugbank.com/drugs/DB12810
    Investigational

    An2718 has been used in trials studying Tinea Pedis.

  10. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long.

    Synonyms: IL-11